Tau kinetics in Alzheimer's disease

被引:11
|
作者
Hier, Daniel B. [1 ,2 ]
Azizi, Sima [1 ]
Thimgan, Matthew S. [3 ]
Wunsch II, Donald C. C. [1 ,4 ]
机构
[1] Missouri Univ Sci & Technol, Dept Elect & Comp Engn, Appl Computat Intelligence Lab, Rolla, MO 65409 USA
[2] Univ Illinois, Dept Neurol & Rehabil, Chicago, IL 60607 USA
[3] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO USA
[4] Natl Sci Fdn, ECCS Div, Alexandria, VA USA
来源
FRONTIERS IN AGING NEUROSCIENCE | 2022年 / 14卷
基金
美国国家科学基金会;
关键词
tau; Alzheimer's disease; CSF levels; plasma levels; steady state kinetics; halflife; turnover; clearance; FIBRILLARY ACIDIC PROTEIN; BRAIN INTERSTITIAL FLUID; NORMAL ORGAN WEIGHTS; II-THE-BRAIN; LONGITUDINAL STABILITY; MOUSE MODEL; PLASMA TAU; SECRETION; TURNOVER; SERUM;
D O I
10.3389/fnagi.2022.1055170
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The cytoskeletal protein tau is implicated in the pathogenesis of Alzheimer's disease which is characterized by intra-neuronal neurofibrillary tangles containing abnormally phosphorylated insoluble tau. Levels of soluble tau are elevated in the brain, the CSF, and the plasma of patients with Alzheimer's disease. To better understand the causes of these elevated levels of tau, we propose a three-compartment kinetic model (brain, CSF, and plasma). The model assumes that the synthesis of tau follows zero-order kinetics (uncorrelated with compartmental tau levels) and that the release, absorption, and clearance of tau is governed by first-order kinetics (linearly related to compartmental tau levels). Tau that is synthesized in the brain compartment can be released into the interstitial fluid, catabolized, or retained in neurofibrillary tangles. Tau released into the interstitial fluid can mix with the CSF and eventually drain to the plasma compartment. However, losses of tau in the drainage pathways may be significant. The kinetic model estimates half-life of tau in each compartment (552 h in the brain, 9.9 h in the CSF, and 10 h in the plasma). The kinetic model predicts that an increase in the neuronal tau synthesis rate or a decrease in tau catabolism rate best accounts for observed increases in tau levels in the brain, CSF, and plasma found in Alzheimer's disease. Furthermore, the model predicts that increases in brain half-life of tau in Alzheimer's disease should be attributed to decreased tau catabolism and not to increased tau synthesis. Most clearance of tau in the neuron occurs through catabolism rather than release to the CSF compartment. Additional experimental data would make ascertainment of the model parameters more precise.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease
    Liu, F
    Zaidi, T
    Iqbal, K
    Grundke-Iqbal, I
    Merkle, RK
    Gong, CX
    FEBS LETTERS, 2002, 512 (1-3) : 101 - 106
  • [42] Tau phosphorylation and aggregation in Alzheimer's disease pathology
    Avila, J
    FEBS LETTERS, 2006, 580 (12) : 2922 - 2927
  • [43] The Role of Tau in Alzheimer's Disease and Related Disorders
    Medeiros, Rodrigo
    Baglietto-Vargas, David
    LaFerla, Frank M.
    CNS NEUROSCIENCE & THERAPEUTICS, 2011, 17 (05) : 514 - 524
  • [44] Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis
    Murray, Patrick S.
    Kirkwood, Caitlin M.
    Gray, Megan C.
    Fish, Kenneth N.
    Ikonomovic, Milos D.
    Hamilton, Ronald L.
    Kofler, Julia K.
    Klunk, William E.
    Lopez, Oscar L.
    Sweet, Robert A.
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 39 (04) : 759 - 773
  • [45] Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease
    Hanger, Diane P.
    Seereeram, Anjan
    Noble, Wendy
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (11) : 1647 - 1666
  • [46] A role for tau at the synapse in Alzheimer's disease pathogenesis
    Pooler, Amy M.
    Noble, Wendy
    Hanger, Diane P.
    NEUROPHARMACOLOGY, 2014, 76 : 1 - 8
  • [47] Implication of tau propagation on neurodegeneration in Alzheimer's disease
    Lamontagne-Kam, Daniel
    Ulfat, Anosha Kiran
    Herve, Vincent
    Vu, Tra-My
    Brouillette, Jonathan
    FRONTIERS IN NEUROSCIENCE, 2023, 17
  • [48] Tau therapeutic strategies for the treatment of Alzheimer's disease
    Churcher, Ian
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (06) : 579 - 595
  • [49] Lactylation of tau in human Alzheimer's disease brains
    Zhang, Xiaoyu
    Liu, Yan
    Rekowski, Michaella J.
    Wang, Ning
    ALZHEIMERS & DEMENTIA, 2025, 21 (02)
  • [50] Phosphorylation of tau by fyn: Implications for Alzheimer's disease
    Lee, G
    Thangavel, R
    Sharma, VM
    Litersky, JM
    Bhaskar, K
    Fang, SM
    Do, LH
    Andreadis, A
    Van Hoesen, G
    Ksiezak-Reding, H
    JOURNAL OF NEUROSCIENCE, 2004, 24 (09): : 2304 - 2312